Nebenwirkungen · Phesgo
Phesgo 600 mg/600 mg solution for injection Phesgo 1 200 mg/600 mg solution for injection · Abschnitt 4.8 · PDF-Seite 21
HOS-147137 · Präparat HOS-099594
Among the patients in Arm A, the incidence of AEs during Cycles 1-3 (intravenous treatment) was 77.5 % (62/80 patients) compared to Cycles 4-6 (subcutaneous treatment) which was 72.5 % (58/80 patients). Among the patients in Arm B, the incidence of AEs during Cycles 1-3 (subcutaneous treatment) was 77.5 % (62/80 patients) compared to Cycles 4-6 (intravenous treatment) which was 63.8 % (51/80 patients), mainly due to higher incidence of local injection site reactions (all Grade 1 or 2) during Phesgo administration. Pre-switching rates (Cycles 1-3) for serious adverse events, Grade 3 adverse events and treatment discontinuations due to adverse events were low (< 6 %) and similar to post-switching rates (Cycles 4-6).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T11:50:00Z · SHA-256 a6c98bf6b55eca9607a319c3be5d77798ac324754cdfd92882fd80d342fc312e · Passage 9df9e3b0a0390906bac20b10c366c3d01fd55ded2213baa1e36a50506a07c156 · Zeichen 32597–33320 im Abschnitt